Randomized Controlled Trial (RCT)

Definition

"A randomized controlled trial (RCT) is often considered the gold standard for making causal inferences."

• Smith and Tanagho's General Urology

Design Diagram

Basic Steps in Conducting an RCT

Randomization - The Heart of an RCT

• Simple randomization - random number tables or computer-generated sequences
• Stratified randomization - population subdivided by key variables (e.g. age, sex) before randomization, ensuring balance on those variables

Blinding

Three Major Confounding Factors in Drug RCTs

1. Variable natural history of disease - Many diseases fluctuate spontaneously; a crossover design or large enough population over sufficient time guards against misattribution.
2. Presence of other diseases and risk factors - Comorbidities, concurrent drugs, and lifestyle factors can influence results. Careful patient selection and accurate histories are required.
3. Subject and observer bias - The placebo effect can produce objective physiological changes in 30-40% of subjects. Single- and double-blind designs are used to quantify and minimize this.

Common RCT Designs

Clinical Trial Phases

CONSORT Checklist

• Report baseline comparability of groups
• State the randomization method and allocation concealment
• Define outcomes a priori with adequate statistical power
• Register the trial in a public registry before enrollment begins

Strengths and Limitations

• Minimizes confounding via randomization
• Allows causal inference (intervention → outcome)
• Double-blinding controls for placebo effect and observer bias

• Expensive and time-consuming
• Ethical constraints (cannot randomize to harmful exposures)
• Strict eligibility criteria reduce generalizability
• Not always feasible (rare diseases, long latency outcomes)
• A well-run RCT still depends on the right question being asked and the right population being enrolled

1. Randomization methods (simple, block, stratified, cluster)
2. Blinding techniques (single, double, triple blind)
3. RCT designs (parallel, crossover, factorial, adaptive, platform)
4. Statistical concepts (power, sample size, p-value, confidence intervals, ITT vs per-protocol analysis)
5. Bias types (selection, performance, detection, attrition, reporting)
6. CONSORT guidelines and reporting standards
7. Ethical considerations (informed consent, equipoise, stopping rules)
8. Clinical trial phases (I-IV)
9. Advantages and limitations of RCTs vs other study designs

Steps in Conducting an RCT

Step 1 - Drawing Up a Protocol

• Aims and objectives of the study
• Research question(s) to be answered
• Inclusion and exclusion criteria for participant selection
• Sample size calculation
• Procedures for allocating subjects to study vs. control groups
• Treatment details - what, when, how, and to whom
• Standardized working procedures and schedules
• Roles and responsibilities of all parties involved
• How outcome will be measured and evaluated

Step 2 - Selecting Reference and Experimental Populations

(a) Reference (Target) Population

• As broad as all of mankind
• Geographically limited (e.g., a city)
• Defined by age, sex, occupation, or clinical condition (e.g., school children, obstetric population)

(b) Experimental (Study) Population

Note: Persons who volunteer to participate often differ from those who do not - this can affect outcome interpretation.

Step 3 - Randomization

• Eliminates selection bias - investigator has no control over group assignment
• Distributes both known AND unknown confounders equally between groups
• Ensures "like is compared with like"
• Every individual gets an equal chance of being in either group

Randomization is done only after the participant has entered the study (i.e., after consent and eligibility confirmation), never before.

Step 4 - Manipulation / Intervention

• A placebo (inert preparation identical in appearance to the active treatment), OR
• Standard/conventional treatment, OR
• No treatment (where ethically permissible)

Step 5 - Follow-Up

• Follow-up must be equal and complete in both groups
• Losses to follow-up (dropouts) must be minimized - they can introduce bias
• A stable, cooperative population should be selected from the outset to reduce attrition
• In a crossover design, after a washout period (to clear the first treatment from the body), the two groups switch interventions - each participant serves as their own control

Step 6 - Assessment of Outcome

• Outcomes must be pre-specified (a priori) in the protocol - changing outcomes after seeing data ("outcome switching") is a major source of bias
• Assessment must be objective, ideally by blinded assessors
• The trial must have sufficient statistical power to detect the expected treatment effect (adequate sample size)

Summary Flowchart

Protocol Development
        ↓
Population Selection (Reference → Experimental)
        ↓
Eligibility Screening + Informed Consent
        ↓
Randomization
   ↙         ↘
Experimental    Control
  Group          Group
(Intervention)  (Placebo/Standard)
        ↓
     Follow-Up
        ↓
  Outcome Assessment
        ↓
  Statistical Analysis
        ↓
  Reporting (CONSORT)